医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Medidata Solutions Announces Enhanced Capabilities and Stand-Alone Option for Medidata Balance

2012年12月05日 PM10:55
このエントリーをはてなブックマークに追加


 

NEW YORK

Medidata Solutions (NASDAQ: MDSO), a leading global provider of cloud-based clinical development solutions, announced that Medidata Balance, the intelligent randomization and trial supply solution, is now being offered as a stand-alone system. This is a new alternative to the Balance solution that is unified with Medidata Rave®, the industry-leading electronic data capture (EDC), management and reporting system.

With powerful enhancements, including new trial supply capabilities and additional ways to conduct randomized trials, Balance introduces a new level of agility in randomization and supply management, whether used with or without Medidata Rave for electronic data collection.

As always, with Medidata Balance the need for software programming and extensive testing is eliminated. Balance brings together all elements of the design and execution of randomization and supply logistics plans into one simple solution operating out of the Medidata Clinical Cloud. The new version includes:

  • A straightforward web interface guiding the creation of the randomization design and supply plans, including definition of complex dosing rules,
  • A powerful dynamic allocation algorithm or permuted block method, now offering integrated list generation, that creates the assignments to arms and strata, and
  • A groundbreaking integrated simulation tool testing the allocation of subjects and confirming the desired level of balance.

The new stand-alone version uses the same clean interface to deliver randomization and supply logistical information to study site staff. Additionally, the cloud-based solution offers site users a simple, intuitive web interface for screening, enrollment, randomization and kit dispensation.

“We continue to enhance the power and versatility of Medidata Balance to enable our customers to be more agile – to quickly adapt to changing needs and priorities, manage increased trial complexity and realize new efficiencies,” said Glen de Vries, president, Medidata Solutions. “With the introduction of this new version of Balance, customers can create and execute trial randomization and supply plans within the pre-validated solution and without being restricted by EDC compatibility.”

Connect with Medidata:

About Medidata Solutions

Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

CONTACT

Edelman
Geoff Curtis
312.233.1253
Geoff.Curtis@edelman.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗